NumerixS Investment Technologies’s NovoCure NVCR Stock Holding History

NumerixS Investment Technologies’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,100	Closed	-$125K	–	568
2020 Q2	$125K	Buy	+2,100	New	+$138K	0.03%	515
2020 Q1	–	Sell	-3,190	Closed	-$269K	–	1194
2019 Q4	$269K	Sell	3,190 -310	-9%	-$25K	0.05%	398
2019 Q3	$262K	Buy	3,500 +1,000	+40%	+$80K	0.07%	313
2019 Q2	$158K	Sell	2,500 -8,446	-77%	-$428K	0.05%	472
2019 Q1	$516K	Buy	10,946 +9,146	+508%	+$440K	0.07%	344
2018 Q4	$59K	Buy	+1,800	New	+$65.8K	0.02%	720
2018 Q3	–	Sell	-6,300	Closed	-$196K	–	1320
2018 Q2	$196K	Buy	6,300 +4,600	+271%	+$128K	0.04%	527
2018 Q1	$36K	Buy	+1,700	New	+$36.6K	0.01%	873
2017 Q3	–	Sell	-600	Closed	-$10K	–	1283
2017 Q2	$10K	Buy	+600	New	+$7.75K	﹤0.01%	1058

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NumerixS Investment Technologies's NVCR Position: Q3 2020 in Review

NumerixS Investment Technologies sold out of NovoCure (NVCR) in Q3 2020, closing a stake of 2,100 shares — an estimated $125K sold.

NumerixS Investment Technologies first reported a position in NVCR in Q2 2017 and held it in 9 quarters. The position peaked at $516K in Q1 2019. 282 funds tracked by Wall St. Rank hold NVCR as of Q3 2020.

NumerixS Investment Technologies reported no remaining NovoCure position as of Q3 2020 after selling out during the quarter.
NumerixS Investment Technologies sold 2,100 NovoCure shares in Q3 2020, an estimated $125K.
NumerixS Investment Technologies first reported a position in NovoCure in Q2 2017 and held it in 9 quarters.
NumerixS Investment Technologies's NovoCure position peaked at $516K in Q1 2019.
282 funds tracked by Wall St. Rank held NovoCure as of Q3 2020.

Based on NumerixS Investment Technologies's 13F filing for Q3 2020.